Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cancer Diseases

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44396   clinical trials with a EudraCT protocol, of which   7408   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    8,106 result(s) found for: Cancer Diseases. Displaying page 68 of 406.
    «« First « Previous 64  65  66  67  68  69  70  71  72  Next» Last»»
    EudraCT Number: 2014-000578-20 Sponsor Protocol Number: CLDK378A2205 Start Date*: 2015-03-16
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A phase II, multi-center, open-label, five-arm study to evaluate the efficacy and safety of oral ceritinib treatment for patients with ALK-Positive Non-Small Cell Lung Cancer (NSCLC) metastatic to ...
    Medical condition: Non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024233 Leptomeningeal metastases LLT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006128 Brain metastases LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed) GB (Completed) DE (Completed) NL (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-003862-40 Sponsor Protocol Number: BO17708 Start Date*: 2006-01-20
    Sponsor Name:F. Hoffmann-La Roche Limited
    Full Title: Estudio multicéntrico, randomizado, doble ciego, controlado con placebo, para evaluar la eficacia y seguridad de bevacizumab en combinación con docetaxel, en comparación con docetaxel más placebo, ...
    Medical condition: Cáncer de mama metastásico Metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    8 10055113 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) BE (Completed) AT (Completed) GB (Completed) SE (Completed) PT (Completed) DE (Completed) LT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-005713-22 Sponsor Protocol Number: TDM4370g/BO21977 Start Date*: 2009-03-18
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Estudio de Fase III multicéntrico, randomizado, abierto, de la eficacia y seguridad de Trastuzumab-MCC-DM1 frente a Capecitabina + Lapatinib en pacientes con cáncer de mama localmente avanzado o me...
    Medical condition: Tratamiento de pacientes con cáncer de mama HER-2 positivo localmente avanzado o metastásico que hayan recibido un taxano y trastuzumab tras progresión de la enfermedad.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027475 Metastatic breast cancer LLT
    9.1 10065430 HER-2 positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) SE (Completed) PT (Completed) DK (Completed) FR (Completed) SI (Completed) GB (Completed) BG (Completed) FI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-003415-31 Sponsor Protocol Number: ARD12166 Start Date*: 2012-01-25
    Sponsor Name:Sanofi-aventis Recherche & Développement
    Full Title: Randomized Phase II Study of Cabazitaxel versus Topotecan in Small Cell Lung Cancer Patients with Progressive Disease during or after a First Line Platinum Based Chemotherapy
    Medical condition: Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041071 Small cell lung cancer stage unspecified PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) FR (Completed) GR (Completed) NO (Completed) IT (Completed) DE (Completed) PL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-000633-40 Sponsor Protocol Number: 61186372NSC3001 Start Date*: 2020-11-18
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins-mutated Locally Advanced...
    Medical condition: EGFR Exon 20ins-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) PT (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000100-11 Sponsor Protocol Number: GO41892 Start Date*: 2020-08-21
    Sponsor Name:F. Hoffman-La Roche Ltd.
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL, CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF TEZOLIZUMAB GIVEN IN COMBINATION WITH CABOZANTINIB VERSUS DOCETAXEL MO...
    Medical condition: Non-small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PT (Completed) BE (Completed) GB (GB - no longer in EU/EEA) GR (Completed) PL (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-003592-34 Sponsor Protocol Number: IMGN853-0419 Start Date*: 2021-12-21
    Sponsor Name:ImmunoGen, Inc.
    Full Title: PICCOLO: A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Rece...
    Medical condition: Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061269 Malignant peritoneal neoplasm PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061328 Ovarian epithelial cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing) BE (Completed) FR (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001359-60 Sponsor Protocol Number: Vasobrain01 Start Date*: 2015-06-16
    Sponsor Name:Aarhus University Hospital
    Full Title: Influence of vasopressors on brain oxygenation and microcirculation in anesthetized patients with cerebral tumors
    Medical condition: Brain oxygenation and microcirculation under administration of Efedrin and Metaoxedrin in patients with cerebral tumor.
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10007050 Cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-000774-58 Sponsor Protocol Number: E7050-703 Start Date*: 2012-01-30
    Sponsor Name:Eisai Inc.
    Full Title: An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination with Cisplatin and Capecitabine versus Cisplatin and Capecitabine Alone in Patients with Advanced or Metastatic Sol...
    Medical condition: Advanced or metastatic solid tumors and previously untreated gastric cancer
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065147 Malignant solid tumor LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-004470-26 Sponsor Protocol Number: ICR-CTSU/2006/10003 Start Date*: 2007-07-05
    Sponsor Name:The Institute of Cancer Research [...]
    1. The Institute of Cancer Research
    2. Kings College London
    Full Title: Triple Negative breast cancer Trial. A randomised phase III trial of carboplatin compared to docetaxel for patients with metastatic or recurrent locally advanced ER-, PR- and HER2- breast cancer
    Medical condition: metastatic or recurrent locally advanced breast cancer that is ER-, PR- (or unknown) and HER2- or known BRCA1/BRCA 2 carriers.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2021-002176-39 Sponsor Protocol Number: V3002401 Start Date*: 2022-02-07
    Sponsor Name:Veru Inc.
    Full Title: ARTEST - A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enobosarm Monotherapy Versus Active Control for the Treatment of AR+/ER+/HER2- Metastatic Breast Cancer in Patients with A...
    Medical condition: (AR+)/estrogen receptor positive(ER+)/human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-005110-30 Sponsor Protocol Number: FASTRELIEF Start Date*: 2017-02-23
    Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
    Full Title: A multicenter randomized trial to evaluate the efficacy of fentanyl pectin nasal spray (FPNS) versus Physician Choice (PC) - Usual Care (UC), in reducing incidental predictable breakthrough pain (I...
    Medical condition: Patients with head and neck cancer .
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-004618-36 Sponsor Protocol Number: CTMX-2009-002 Start Date*: 2021-03-15
    Sponsor Name:CytomX Therapeutics, Inc.
    Full Title: A Phase 2, Open-Label Study to Evaluate the Safety and Antitumor Activity of CX-2009 in Advanced HR-Positive/HER2-Negative Breast Cancer and of CX-2009 as Monotherapy and in Combination with CX-072...
    Medical condition: HR-positive/HER2-negative breast cancer Triple-negative breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001828-36 Sponsor Protocol Number: ABP-2019 Start Date*: 2020-02-21
    Sponsor Name:Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest
    Full Title: Advancing Brigatinib Properties in anaplastic lymphoma kinase positive non-small cell lung cancer (ALK+ NSCLC) patients by deep phenotyping
    Medical condition: Anaplastic lymphoma kinase positive non-small cell lung cancer (ALK+ NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-000058-77 Sponsor Protocol Number: ESPADURVA Start Date*: 2019-11-25
    Sponsor Name:University Hospital Essen
    Full Title: Prospective Phase-II Trial of induction chemotherapy and chemoradiotherapy plus/minus the PD-L1 antibody durvalumab followed by surgery or definitive chemoradiation boost and consolidation durvalum...
    Medical condition: non-small cell lung cancer stages IIIA (N2) and selected resectable stages IIIB
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003507-19 Sponsor Protocol Number: HOPE9 Start Date*: 2020-09-10
    Sponsor Name:AZIENDA USL TOSCANA NORD OVEST
    Full Title: “Phase III, randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy of pre-surgical HPV 9-valent vaccination in women treated with electrosurgical excision with diat...
    Medical condition: Prevention of recurrence after a first episode of high-grade cervical intraepithelial neoplasia (CIN2 +) up to initially invasive cervical cancer (FIGO IA1)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10008229 Cervical cancer LLT
    21.1 100000004872 10056576 Cervical intraepithelial neoplasia LLT
    21.1 10022891 - Investigations 10064328 Human papilloma virus test positive PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002393-12 Sponsor Protocol Number: PRODIGE49 Start Date*: 2016-08-26
    Sponsor Name:Fédération Francophone de Cancérologie Digestive
    Full Title: Systemic oxaliplatin or in intra-arterial chemotherapy combined with LV5FU2 and targeted therapy in first-line treatment of metastatic colorectal cancer restricted to the liver
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001863-21 Sponsor Protocol Number: FIOL Start Date*: 2018-08-14
    Sponsor Name:Vestre Viken Hospital Trust
    Full Title: First-line treatment with osimertinib in EGFR-mutated non-small cell lung cancer, coupled to extensive translational studies.
    Medical condition: Lung cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) LT (Trial now transitioned) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000131-51 Sponsor Protocol Number: 1921 Start Date*: 2019-03-07
    Sponsor Name:Zealand University Hospital
    Full Title: Preoperative endoscopic treatment with fosfomycin and metronidazole in patients with right-sided colon cancer and colon adenoma: a clinical proof-of-concept intervention study MEFO trial
    Medical condition: Colon cancer in track 1. Colon adenoma in track 2.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009944 Colon cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10048832 Colon adenoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-003449-14 Sponsor Protocol Number: GO41836 Start Date*: 2020-07-14
    Sponsor Name:Genentech Inc.
    Full Title: A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF RO7198457 IN COMBINATION WITH ATEZOLIZUMAB VERSUS ATEZOLIZUMAB ALONE FOLLOWING ADJUVANT PLATINUM-DOUBLET CHEMOTHE...
    Medical condition: Non-small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029518 Non-small cell lung cancer stage II PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 64  65  66  67  68  69  70  71  72  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 03 18:46:20 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA